Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX -0.86%6 Debt-to-Equity is 0.35 as of Jun. 2026, which is 3% above its 10-year median of 0.34. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 702 Medical Devices & Instruments companies, 20/20 Biolabs ranks worse than 60.26% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for 20/20 Biolabs's Debt-to-Equity or its related term are showing as below:
AIDX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -71.53 Med: 0.34 Max: 10.73
Current: 0.34
During the past 3 years, the highest Debt-to-Equity Ratio of 20/20 Biolabs was 10.73. The lowest was -71.53. And the median was 0.34.
AIDX's Debt-to-Equity is ranked worse than 60.26% of 702
companies
in the Medical Devices & Instruments industry
Industry Median: 0.22
vs AIDX: 0.34
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
20/20 Biolabs Debt-to-Equity Related Terms
20/20 Biolabs Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for 20/20 Biolabs's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIDX vs STME, TRIB, VVOS: Debt-to-Equity Comparison
For the Medical Devices subindustry, 20/20 Biolabs's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
20/20 Biolabs (AIDX) has a Debt-to-Equity of 0.35 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 20/20 Biolabs and its competitors. This is near median its historical median of 0.34. According to the industry distribution chart, 20/20 Biolabs ranks #423 out of 702 companies in the Medical Devices & Instruments industry, placing it in the top 60.3%.
Is 20/20 Biolabs' Debt-to-Equity too high?
20/20 Biolabs' current Debt-to-Equity of 0.35 is near median its 10-year median of 0.34. The Medical Devices & Instruments industry median Debt-to-Equity is 0.22. 20/20 Biolabs' value of 0.35 is 59.1% above this industry median. Based on the distribution chart, 20/20 Biolabs ranks #423 out of 702 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' Debt-to-Equity compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #423 out of 702 companies for Debt-to-Equity. This places 20/20 Biolabs in the lower half of its industry. The industry median Debt-to-Equity is 0.22. 20/20 Biolabs' value of 0.35 is 59.1% above this benchmark. While the company's 10-year median is 0.34 vs. the industry median of 0.22, 20/20 Biolabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 20/20 Biolabs's current Debt-to-Equity of 0.35 is 59.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 20/20 Biolabs and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 20/20 Biolabs's current Debt-to-Equity is 0.35, which is near median its own 10-year median of 0.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current Debt-to-Equity of 0.35. The current Debt-to-Equity is 0.35, which is near median its 10-year median of 0.34 and 59.1% above the Medical Devices & Instruments industry median of 0.22. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current Debt-to-Equity is 0.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
